Health
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
COPENHAGEN, Denmark, May 02, 2025--Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), following at least one prior systemic therapy.
About this update from Genmab A/s
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1301,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/b99ad1d16b7f09d4625183f33d6f9758"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a3A.YSywDE05.XYir_NBow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b99ad1d16b7f09d4625183f33d6f9758","width":960,"height":280},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7XTzd1cpOPDkMM7aysjWug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b99ad1d16b7f09d4625183f33d6f9758","width":1200,"height":350}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trial","length":157,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full results from the trial will be submitted for presentation at an upcoming medical conference in 2025","length":104,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":261,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, May 02, 2025--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), following at least one prior systemic therapy.","length":508,"tagName":"p"},{"type":"text","content":"The decision to submit the sBLA is supported by positive topline results from the Phase 3 EPCORE FL-1 trial evaluating epcoritamab plus R2 versus R2 alone in adult patients with R/R FL. Based on an interim analysis conducted by an Independent Data Monitoring Committee (IDMC) review, the study met one of its dual primary endpoints of ORR (Complete Response plus Partial Response, p-value < 0.0001). The safety profile of epcoritamab plus R2 in adult patients with R/R FL was consistent with the known safety profiles of the individual regimens (epcor...